Pila Pharma   Report issue

For profit Phase 2
Founded: Malmo Sweden (2014)
Status: Left NME R&D (2022)

Organization Overview

First Clinical Trial
2017
NCT03278158
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Pila Pharma

Active Ingredients

Drugs in Phase 2 Trials (1)

Key: Pila Pharma (0) Acquired (1)

xen-d0501 (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Overview

  • Highest Phase: None
  • # of Trials: 4
  • # of Trial APIs: 1